Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call

Rhea-AI Summary

Medexus Pharmaceuticals (OTCQX: MEDXF) will host a conference call at 8:00 a.m. ET on June 26, 2026 to review results for its fourth fiscal quarter and fiscal year ended March 31, 2026.

Financial statements and MD&A are expected to be filed after markets close on June 25, 2026.

News Market Reaction – MEDXF

-1.39%

-1.39% Session close to close

In the Jun 17 session, MEDXF declined 1.39%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026.

To participate in the call, please dial the following numbers:

888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers

Access code: 515731

A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:

https://www.webcaster5.com/Webcast/Page/2010/54174

A replay of the call will be available approximately one hour following the end of the call through Friday, July 10, 2026. To access the replay, please dial the following numbers -

877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers

Conference ID: 54174

A replay of the webcast will be available on the Investors section of Medexus's corporate website until Saturday, June 26, 2027.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hemato-oncology and rheumatology and allergy. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

Contacts

Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com

Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com

Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca

Forward-looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301705

FAQ

When is the Medexus (MEDXF) Q4 and fiscal 2026 earnings conference call?

The Medexus Q4 and fiscal 2026 conference call is scheduled for 8:00 a.m. Eastern Time on Friday, June 26, 2026. According to Medexus, the call will review results for the quarter and year ended March 31, 2026.

How can investors join the Medexus (MEDXF) June 26, 2026 earnings call?

Investors can join by dialing 888-506-0062 (Canada/U.S.) or +1 973-528-0011 (international) with access code 515731. According to Medexus, a live webcast will also be available in the Investors section of the company’s corporate website.

Where can I listen to the Medexus (MEDXF) Q4 2026 earnings webcast replay?

A replay of the Medexus earnings webcast will be available in the Investors section of the company’s website until June 26, 2027. According to Medexus, a replay of the call audio will also be accessible by dedicated dial-in numbers.

What replay dial-in numbers are available for the Medexus (MEDXF) June 26, 2026 call?

The replay can be accessed by dialing 877-481-4010 in Canada and the U.S. or +1 919-882-2331 internationally, using conference ID 54174. According to Medexus, the replay will be available through Friday, July 10, 2026.

What financial period will Medexus (MEDXF) discuss on the June 26, 2026 call?

Medexus will discuss results for its fourth fiscal quarter and fiscal year ended March 31, 2026. According to Medexus, related financial statements and MD&A are expected to be filed after markets close on June 25, 2026.